CY1120600T1 - Αντισωματα κατα του υποδοχεα φυλλικου αλφα και χρησεις αυτων - Google Patents
Αντισωματα κατα του υποδοχεα φυλλικου αλφα και χρησεις αυτωνInfo
- Publication number
- CY1120600T1 CY1120600T1 CY181100260T CY181100260T CY1120600T1 CY 1120600 T1 CY1120600 T1 CY 1120600T1 CY 181100260 T CY181100260 T CY 181100260T CY 181100260 T CY181100260 T CY 181100260T CY 1120600 T1 CY1120600 T1 CY 1120600T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- antibodies
- methods
- alpha
- receptor
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Στο παρόν περιγράφονται αντισώματα και κλάσματα δέσμευσης αντιγόνου αυτών, τα οποία είναι ειδικά για τον υποδοχέα φυλλικού άλφα, συναφή πολυνουκλεοτίδια, φορείς έκφρασης και κύτταρα που εκφράζουν τα αντισώματα που περιγράφονται. Επίσης παρέχονται μέθοδοι χρήσης των αντισωμάτων που περιγράφονται και των κλασμάτων δέσμευσης αντιγόνου αυτών, και συναφή κιτ. Επίσης στο παρόν παρέχονται μέθοδοι για τη διάγνωση καρκίνων, όπως καρκίνου του μαστού, καρκίνου του θυρεοειδούς, καρκίνου του παχέος εντέρου και ορθού, καρκίνου του ενδομητρίου, καρκίνου των σαλπίγγων, καρκίνου των ωοθηκών ή καρκίνου του πνεύμονα, χρησιμοποιώντας τα αντισώματα που περιγράφονται και τα κλάσματα δέσμευσης αντιγόνου αυτών. Οι μέθοδοι αφορούν τον προσδιορισμό της ποσότητας του υποδοχέα φυλλικού άλφα σε δείγμα που προέρχεται από ένα υποκείμενο και σύγκριση του εν λόγω επιπέδου με το επίπεδο του υποδοχέα φυλλικού άλφα σε δείγμα ελέγχου ή δείγμα αναφοράς.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161508444P | 2011-07-15 | 2011-07-15 | |
US201261604412P | 2012-02-28 | 2012-02-28 | |
US201261604954P | 2012-02-29 | 2012-02-29 | |
PCT/US2012/046672 WO2013012722A1 (en) | 2011-07-15 | 2012-07-13 | Anti-folate receptor alpha antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120600T1 true CY1120600T1 (el) | 2019-12-11 |
Family
ID=46516898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY181100260T CY1120600T1 (el) | 2011-07-15 | 2018-03-01 | Αντισωματα κατα του υποδοχεα φυλλικου αλφα και χρησεις αυτων |
Country Status (20)
Country | Link |
---|---|
US (4) | US8475795B2 (el) |
EP (2) | EP2731972B1 (el) |
JP (2) | JP6220333B2 (el) |
CN (2) | CN103998467B (el) |
AU (3) | AU2012284321C1 (el) |
BR (1) | BR112014001030A2 (el) |
CA (1) | CA2841725C (el) |
CY (1) | CY1120600T1 (el) |
DK (1) | DK2731972T3 (el) |
ES (2) | ES2824498T3 (el) |
HR (1) | HRP20180353T1 (el) |
HU (1) | HUE036929T2 (el) |
LT (1) | LT2731972T (el) |
PL (1) | PL2731972T3 (el) |
PT (1) | PT2731972T (el) |
RS (1) | RS56985B1 (el) |
SG (1) | SG10201605278PA (el) |
SI (1) | SI2731972T1 (el) |
TR (1) | TR201802838T4 (el) |
WO (1) | WO2013012722A1 (el) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY171234A (en) | 2010-02-24 | 2019-10-04 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
IL303208A (en) | 2011-04-01 | 2023-07-01 | Immunogen Inc | Methods for increasing the effectiveness of FOLR1 cancer therapy |
CA2841725C (en) * | 2011-07-15 | 2021-03-09 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
NZ726258A (en) | 2012-08-31 | 2019-07-26 | Immunogen Inc | Antibodies and uses thereof to detect folate receptor 1 |
AU2014284212B2 (en) | 2013-06-20 | 2019-09-12 | Eisai, Inc. | Methods for treatment of ovarian cancer |
KR20230145514A (ko) | 2013-08-30 | 2023-10-17 | 이뮤노젠 아이엔씨 | 엽산 수용체 1의 검출을 위한 항체 및 분석 |
EP3140653B1 (en) * | 2014-05-08 | 2022-05-11 | Novodiax, Inc. | Direct immunohistochemistry assay |
EP4141032B1 (en) | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
MX2017013390A (es) | 2015-04-17 | 2018-06-13 | Morphotek Inc | Método para el tratamiento de cáncer pulmonar. |
RU2749865C2 (ru) | 2015-09-17 | 2021-06-17 | Иммьюноджен, Инк. | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты |
JP7227123B2 (ja) | 2016-08-12 | 2023-02-21 | エル.イー.エー.エフ. ホールディングス グループ エルエルシー | αおよびγ-Dポリグルタミン酸化抗葉酸剤およびその使用 |
EP3544999A1 (en) * | 2016-11-23 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
CN107353325B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽1及其应用 |
CN107446021B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽5及其应用 |
CN107793471B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽4及其应用 |
CN107446020B (zh) * | 2017-07-28 | 2019-10-01 | 中国药科大学 | 叶酸受体α特异性结合肽2及其应用 |
AU2018328187A1 (en) * | 2017-09-05 | 2020-03-26 | Immunogen, Inc. | Methods for detection of folate receptor 1 in a patient sample |
EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | PRALATREXATE ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
CN111954531A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | α聚谷氨酸化培美曲塞及其用途 |
US11771700B2 (en) | 2018-02-14 | 2023-10-03 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
JP7433236B2 (ja) | 2018-03-13 | 2024-02-19 | フェインズ セラピューティクス,インコーポレーテッド | 抗葉酸受容体1抗体及びその使用 |
KR102275930B1 (ko) * | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
TW202019472A (zh) * | 2018-07-09 | 2020-06-01 | 大陸商艾比瑪特生物醫藥(上海)有限公司 | 葉酸受體阿法特異性抗體 |
CN111393528B (zh) * | 2020-01-19 | 2023-01-31 | 中国药科大学 | 一种靶向叶酸受体α的单链抗体及其应用 |
WO2021247821A1 (en) * | 2020-06-03 | 2021-12-09 | The Wistar Institute Of Anatomy And Biology | Monoclonal antibodies against human siglec-9 and use thereof for immunotherapy |
AU2022284860A1 (en) * | 2021-06-04 | 2023-12-14 | Immunogen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
CN117700556B (zh) * | 2024-02-05 | 2024-04-12 | 苏州百道医疗科技有限公司 | 一种抗FRα小鼠单克隆抗体及其应用 |
CN117700557B (zh) * | 2024-02-05 | 2024-04-30 | 卡秋(江苏)生物科技有限公司 | 一种特异性结合叶酸受体α的抗体或抗原结合片段 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US6770445B1 (en) | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
US20080131366A1 (en) | 2003-03-17 | 2008-06-05 | Manohar Ratnam | Folate Receptor Gene Modulation For Cancer Diagnosis And Therapy |
US20040235108A1 (en) | 2003-05-23 | 2004-11-25 | Luigi Grasso | Monoclonal antibodies that specifically bind a tumor antigen |
EP2316857A1 (en) | 2004-02-12 | 2011-05-04 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
CA2602585A1 (en) | 2005-03-30 | 2006-10-05 | Purdue Research Foundation | Method for cancer prognosis using cellular folate vitamin receptor quantification |
JP2009521206A (ja) * | 2005-04-22 | 2009-06-04 | モルフォテック、インク. | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
US7754698B2 (en) | 2007-01-09 | 2010-07-13 | Isis Pharmaceuticals, Inc. | Modulation of FR-alpha expression |
FR2918994B1 (fr) | 2007-07-20 | 2012-10-19 | Rhodia Operations | Formulations de diesters d'acide carboxylique et leur utilisation pour le traitement de materiaux. |
WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
US20110177525A1 (en) | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
MX343607B (es) * | 2010-11-05 | 2016-11-11 | Morphotek Inc | Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. |
JP2014508165A (ja) | 2011-03-02 | 2014-04-03 | モルフォテック、インク. | 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与 |
CA2841725C (en) * | 2011-07-15 | 2021-03-09 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
-
2012
- 2012-07-13 CA CA2841725A patent/CA2841725C/en active Active
- 2012-07-13 RS RS20180252A patent/RS56985B1/sr unknown
- 2012-07-13 LT LTEP12736054.3T patent/LT2731972T/lt unknown
- 2012-07-13 US US13/548,775 patent/US8475795B2/en active Active
- 2012-07-13 SG SG10201605278PA patent/SG10201605278PA/en unknown
- 2012-07-13 BR BR112014001030A patent/BR112014001030A2/pt not_active Application Discontinuation
- 2012-07-13 JP JP2014520368A patent/JP6220333B2/ja active Active
- 2012-07-13 DK DK12736054.3T patent/DK2731972T3/en active
- 2012-07-13 WO PCT/US2012/046672 patent/WO2013012722A1/en active Application Filing
- 2012-07-13 PT PT127360543T patent/PT2731972T/pt unknown
- 2012-07-13 TR TR2018/02838T patent/TR201802838T4/tr unknown
- 2012-07-13 PL PL12736054T patent/PL2731972T3/pl unknown
- 2012-07-13 CN CN201280043606.2A patent/CN103998467B/zh active Active
- 2012-07-13 ES ES17196948T patent/ES2824498T3/es active Active
- 2012-07-13 ES ES12736054.3T patent/ES2663556T3/es active Active
- 2012-07-13 AU AU2012284321A patent/AU2012284321C1/en active Active
- 2012-07-13 EP EP12736054.3A patent/EP2731972B1/en active Active
- 2012-07-13 CN CN201611025725.1A patent/CN107011439B/zh active Active
- 2012-07-13 EP EP17196948.8A patent/EP3330291B1/en active Active
- 2012-07-13 SI SI201231234T patent/SI2731972T1/en unknown
- 2012-07-13 HU HUE12736054A patent/HUE036929T2/hu unknown
-
2013
- 2013-03-13 US US13/800,575 patent/US8834877B2/en active Active
-
2014
- 2014-08-04 US US14/451,044 patent/US9599621B2/en active Active
-
2017
- 2017-02-16 US US15/434,326 patent/US10101343B2/en active Active
- 2017-04-11 AU AU2017202365A patent/AU2017202365B2/en active Active
- 2017-09-29 JP JP2017190224A patent/JP6526143B2/ja active Active
-
2018
- 2018-02-27 HR HRP20180353TT patent/HRP20180353T1/hr unknown
- 2018-03-01 CY CY181100260T patent/CY1120600T1/el unknown
- 2018-09-26 AU AU2018236755A patent/AU2018236755B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120600T1 (el) | Αντισωματα κατα του υποδοχεα φυλλικου αλφα και χρησεις αυτων | |
CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
CY1124558T1 (el) | Προβλεψη επιτοπων τ κυτταρων χρησιμων για εμβολιασμο | |
CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
CY1124176T1 (el) | Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων | |
CY1122720T1 (el) | Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii | |
CO2018010475A2 (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
CY1126115T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
CY1122022T1 (el) | Αναπτυξη και χρηση φθοριζοντων ανιχνευτων αδεσμευτης χολερυθρινης | |
CL2019002645A1 (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra cánceres positivos para prame. | |
MX2020004567A (es) | Metodos diagnosticos y terapeuticos para el cancer. | |
CO2018000885A2 (es) | Constructos de anticuerpo biespecíficos que se unen a mesotelina y cd3 | |
PE20180950A1 (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador | |
WO2012061759A3 (en) | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers | |
CU20180033A7 (es) | Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll | |
NZ742290A (en) | Binding molecules that inhibit cancer growth | |
EA201791578A1 (ru) | Панель биомаркеров для обнаружения рака | |
NI201100182A (es) | Anticuerpos específicos para cadherina - 17 | |
DK2211180T3 (da) | Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer | |
CY1123743T1 (el) | Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου | |
NZ742911A (en) | Peptide microarrays and novel biomarkers for celiac disease | |
NZ629074A (en) | Biomarkers for gastric cancer and uses thereof | |
UY36200A (es) | Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado | |
BR112013009551A2 (pt) | anticorpos |